Current treatment of inflammatory bowel disease in children

Digestive and Liver Disease

Volumn 40, Issue 1, 2008, Pages 16-21

  Markowitz, J ^a  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

5 ASA; Biologic therapy; Children; Corticosteroids; IBD; Immunomodulators; Nutritional therapy

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CONTRACEPTIVE AGENT; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; OLSALAZINE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; TACROLIMUS; TIOGUANINE;

ACNE; ADRENAL INSUFFICIENCY; ALLERGIC PNEUMONITIS; AVASCULAR NECROSIS; BONE MARROW SUPPRESSION; CALORIC INTAKE; CANCER RISK; CATARACT; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; CUSHING SYNDROME; DEMYELINATING DISEASE; DIETARY INTAKE; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FIRST PASS EFFECT; GLAUCOMA; GLUCOSE INTOLERANCE; GROWTH RETARDATION; HEART FAILURE; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LIVER FUNCTION TEST; LIVER TOXICITY; LUNG TOXICITY; LUPUS LIKE SYNDROME; LYMPHOMA; MAINTENANCE THERAPY; MOOD DISORDER; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NUTRITIONAL DEFICIENCY; NUTRITIONAL STATUS; PANCREATITIS; PATIENT COMPLIANCE; RECURRENT DISEASE; REMISSION; RISK REDUCTION; SERUM SICKNESS; SHORT SURVEY; SIDE EFFECT; STOMATITIS; T CELL LYMPHOMA; TERATOGENICITY; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

CHILD; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; NUTRITIONAL SUPPORT; TREATMENT OUTCOME;

EID: 37049008926     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.07.167     Document Type: Short Survey

References (34)

1. Lochs H, Dejong C, Hammarqvist F, Hebuterne X, Leon-Sanz M, Schutz T, et al. DGEM (German Society for Nutritional Medicine); Lubke H, Bischoff S, Engelmann N, Thul P. ESPEN (European Society for Parenteral and Enteral Nutrition). ESPEN Guidelines on Enteral Nutrition: Gastroenterology. Clin Nutr 2006;25:260-74.
2. Heuschkel R.B., Menache C.C., Megerian J.T., and Baird A.E. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 31 (2000) 8-150
3. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2001:CD000542.
4. Hanauer S.B. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 20 Suppl. 4 (2004) 60-65
5. Velayos F.S., Terdiman J.P., and Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100 (2005) 1345-1353
6. Desreumaux P., and Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther 24 Suppl. 1 (2006) 2-9
7. Iofel E., Chawla A., Daum F., and Markowitz J. Mesalamine intolerance mimics symptoms of active inflammatory bowel disease. J Pediatr Gastroenterol Nutr 34 (2002) 73-76
8. Markowitz J., Hyams J., Mack D., LeLeiko N., Evans J., Kugathasan S., et al. Corticosteroid therapy in the age of infliximab: acute and 1 year outcomes in newly diagnosed children with Crohn disease. Clin Gastroenterol Hepatol 4 (2006) 1124-1129
9. Hyams J., Markowitz J., Lerer T., Griffiths A., Mack D., Bousvaros A., et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 4 (2006) 1118-1123
10. Escher J.C., and European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 16 (2004) 47-54
11. Markowitz J., Grancher K., Kohn N., and Daum F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use 1990-2000. Am J Gastroenterol 97 (2002) 928-932
12. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 111 (2003) 1133-1145
13. Markowitz J., Grancher K., Kohn N., Lesser M., and Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 119 (2000) 895-902
14. Hanauer S.B., Korelitz B.I., Rutgeerts P., Peppercorn M.A., Thisted R.A., Cohen R.D., et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127 (2004) 723-729
15. Kirschner B.S. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115 (1998) 813-821
16. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Theoret Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118 (2000) 705-713
17. Derijks L.J., Gilissen L.P., Hooymans P.M., and Hommes D.W. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 24 (2006) 715-729
18. Kandiel A., Fraser A.G., Korelitz B.I., Brensinger C., and Lewis J.D. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
19. Lewis J.D., Schwartz J.S., and Lichtenstein G.R. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 18 (2000) 1018-1024
20. Mack D.R., Young R., Kaufman S.S., Ramey L., and Vanderhoof J.A. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 132 (1998) 830-835
21. Ravikumara M., Hinsberger A., and Spray C.H. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr 44 (2007) 427-430
22. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Update of: Cochrane Database Syst Rev 2003:CD003459. Cochrane Database Syst Rev 2005:CD003459.
23. Shibolet O, Regushevskaya E, Brezis M, Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 2005:CD004277.
24. Gonzalez-Lama Y., Abreu L., Vera M.I., Pastrana M., Tabernero S., Revilla J., et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm Bowel Dis 11 (2005) 8-15
25. Bousvaros A., Kirschner B.S., Werlin S.L., Parker-Hartigan L., Daum F., Freeman K.B., et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 137 (2000) 794-799
26. Rutgeerts P., Van Assche G., and Vermeire S. Infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 23 (2006) 451-463
27. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., et al., REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132 (2007) 863-873
28. Gisbert J.P., Gonzalez-Lama Y., and Mate J. Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 25 (2007) 19-37
29. Fanjiang G., Russell G.H., and Katz A.J. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 44 (2007) 312-317
30. Barrie A., and Plevy S. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab. Gastroenterol Clin North Am 35 (2006) 883-893
31. Borrelli O., Bascietto C., Viola F., Bueno de Mesquita M., Barbato M., Mancini V., et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis 36 (2004) 342-347
32. Bratcher J.M., and Korelitz B.I. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin Drug Saf 5 (2006) 9-16
33. Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2 (2004) 542-553
34. Mackey A.C., Green L., Liang L.C., Dinndorf P., and Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267